Dengue vaccines for travelers

References

• Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res.33(4), 330–342 (2002).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Schwartz E. Dengue in travelers. N. Engl. J. Med.353(9), 924–932 (2005).
   PubMed Web of Science ®Google Scholar
• Sharp TW, Wallace MR, Hayes CG et al. Dengue fever in U.S. troops during Operation Restore Hope, Somalia, 1992–1993. Am. J. Trop. Med. Hyg.53(1), 89–94 (1995).
   PubMed Web of Science ®Google Scholar
• Sharp TW, DeFraites RF, Thornton SA, Burans JP, Wallace MR. Illness in journalists and relief workers involved in international humanitarian assistance efforts in Somalia, 1992–93. J. Travel Med.2(2), 70–76 (1995).
   PubMedGoogle Scholar
• Gambel JM, Drabick JJ, Swalko MA, Henchal EA, Rossi CA, Martinez-Lopez L. Dengue among United Nations mission in Haiti personnel, 1995: implications for preventive medicine. Mil. Med.164(4), 300–302 (1999).
   PubMedGoogle Scholar
• Cobelens FG, Groen J, Osterhaus AD, Leentvaar-Kuipers A, Wertheim-van Dillen PM, Kager PA. Incidence and risk factors of probable dengue virus infection among Dutch travellers to Asia. Trop. Med. Int. Health7(4), 331–338 (2002).
   PubMed Web of Science ®Google Scholar
• Potasman I, Srugo I, Schwartz E. Dengue seroconversion among Israeli travelers to tropical countries. Emerg. Infect. Dis.5(6), 824–827 (1999).
   PubMed Web of Science ®Google Scholar
• Steffen R, Heusser R, Machler R et al. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy. Bull. World Health Organ.68(3), 313–322 (1990).
   PubMed Web of Science ®Google Scholar
• Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA272(11), 885–889 (1994).
   PubMed Web of Science ®Google Scholar
• Stephan C, Allwinn R, Brodt HR, Knupp B, Preiser W, Just-Nubling G. Travel-acquired dengue infection: clinical spectrum and diagnostic aspects. Infection30(4), 225–258 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien D, Tobin S, Brown GV, Torresi J. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin. Infect. Dis.33(5), 603–609 (2001).
   PubMed Web of Science ®Google Scholar
• Stienlauf S, Segal G, Sidi Y, Schwartz E. Epidemiology of travel-related hospitalization. J. Travel Med.12(3), 136–141 (2005).
   PubMedGoogle Scholar
• Freedman D; The GeoSentinel Group. GeoSentinel: the Global Emerging Infections Sentinel Network of the International Society of Travel Medicine. J. Travel Med.6, 94–98 (1999).
   PubMed Web of Science ®Google Scholar
• Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N. Engl. J. Med.354(2), 119–130 (2006).
   PubMed Web of Science ®Google Scholar
• Schwartz E, Weld L, Wilder-Smith A. Seasonality, annual trends, and characteristics of dengue in ill returned travelers (1997–2006). Emerging Infect. Dis. (In press) (2008).
   PubMedGoogle Scholar
• Jelinek T, Muhlberger N, Harms G et al. Epidemiology and clinical features of imported dengue fever in Europe: sentinel surveillance data from TropNetEurop. Clin. Infect. Dis.35(9), 1047–1052 (2002).
   PubMed Web of Science ®Google Scholar
• Wichmann O, Mühlberger N, Jelinek T. Dengue – the underestimated risk in travellers. Dengue Bull.27, 126–137 (2003).
   Google Scholar
• Wilson ME, Freedman DO. Etiology of travel-related fever. Curr. Opin. Infect. Dis.20(5), 449–453 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartz E, Mendelson E, Sidi Y. Dengue fever among travelers. Am. J. Med.101(5), 516–520 (1996).
   PubMed Web of Science ®Google Scholar
• Jensenius M, Gundersen SG, Vene S, Bruu AL. [Dengue fever imported to Norway. Serologically confirmed cases 1991–96]. Tidsskr. Nor. Laegeforen.117(29), 4230–4233 (1997).
   PubMedGoogle Scholar
• Seet RC, Quek AM, Lim EC. Post-infectious fatigue syndrome in dengue infection. J. Clin. Virol.38(1), 1–6 (2007).
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol.5(7), 518–528 (2007).
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G. Dengue: an update. Lancet Infect. Dis.2(1), 33–42 (2002).
   PubMed Web of Science ®Google Scholar
• Lum LC, Lam SK, George R, Devi S. Fulminant hepatitis in dengue infection. Southeast Asian J. Trop. Med. Public Health24(3), 467–471 (1993).
   PubMedGoogle Scholar
• Ling LM, Wilder-Smith A, Leo YS. Fulminant hepatitis in dengue haemorrhagic fever. J. Clin. Virol.38(3), 265–268 (2007).
   PubMed Web of Science ®Google Scholar
• Seet RC, Lim EC, Wilder-Smith EP. Acute transverse myelitis following dengue virus infection. J. Clin. Virol.35(3), 310–312 (2006).
   PubMed Web of Science ®Google Scholar
• Solomon T, Dung NM, Vaughn DW et al. Neurological manifestations of dengue infection. Lancet355(9209), 1053–1059 (2000).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Tambyah PA. Severe dengue virus infection in travelers. J. Infect. Dis.195(8), 1081–1083 (2007).
   PubMedGoogle Scholar
• Wichmann O, Gascon J, Schunk M et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J. Infect. Dis.195(8), 1089–1096 (2007).
   PubMed Web of Science ®Google Scholar
• Gamble J, Bethell D, Day NP et al. Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock? Clin. Sci. (Lond.)98(2), 211–216 (2000).
   PubMed Web of Science ®Google Scholar
• Rosen L. The Emperor’s New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever. Am. J. Trop. Med. Hyg.26(3), 337–343 (1977).
   PubMed Web of Science ®Google Scholar
• Gubler DJ. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev.11(3), 480–496 (1998).
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis.181(1), 2–9 (2000).
   PubMed Web of Science ®Google Scholar
• Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med.42(5), 311–328 (1970).
   PubMed Web of Science ®Google Scholar
• Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg.38(1), 172–180 (1988).
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G, Valdes L et al. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am. J. Epidemiol.152(9), 793–799 (2000).
   PubMed Web of Science ®Google Scholar
• Kuhn RJ, Zhang W, Rossmann MG et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell108(5), 717–725 (2002).
   PubMed Web of Science ®Google Scholar
• Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis.140(4), 527–533 (1979).
   PubMed Web of Science ®Google Scholar
• Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev. Infect. Dis.11(Suppl. 4), S830–S839 (1989).
   PubMedGoogle Scholar
• Halstead SB, Venkateshan CN, Gentry MK, Larsen LK. Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J. Immunol.132(3), 1529–1532 (1984).
   PubMed Web of Science ®Google Scholar
• Halstead SB, O’Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med.146(1), 201–217 (1977).
   PubMed Web of Science ®Google Scholar
• Halstead SB. Immune enhancement of viral infection. Prog. Allergy31, 301–364 (1982).
   PubMedGoogle Scholar
• Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud. Publica.11(4), 223–227 (2002).
   PubMedGoogle Scholar
• Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever–dengue shock syndrome (DHF/DSS). Immunol. Cell Biol.85(1), 43–45 (2007).
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Dejnirattisai W, Xu XN et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med.9(7), 921–927 (2003).
   PubMed Web of Science ®Google Scholar
• Dong T, Moran E, Vinh Chau N et al. High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS ONE2(12), e1192 (2007).
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Duangchinda T, Dejnirattisai W et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol.176(6), 3821–3829 (2006).
   PubMed Web of Science ®Google Scholar
• Avirutnan P, Punyadee N, Noisakran S et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis.193(8), 1078–1088 (2006).
   PubMed Web of Science ®Google Scholar
• Kochel TJ, Watts DM, Gozalo AS, Ewing DF, Porter KR, Russell KL. Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J. Infect. Dis.191(6), 1000–1004 (2005).
   PubMed Web of Science ®Google Scholar
• Monath TP. Dengue and yellow fever – challenges for the development and use of vaccines. N. Engl. J. Med.357(22), 2222–2225 (2007).
   PubMed Web of Science ®Google Scholar
• Halstead SB, Deen J. The future of dengue vaccines. Lancet360(9341), 1243–1245 (2002).
   PubMed Web of Science ®Google Scholar
• Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull. World Health Organ.83(4), 308–314 (2005).
   PubMed Web of Science ®Google Scholar
• Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr. Opin. Infect. Dis.18(5), 387–394 (2005).
   PubMed Web of Science ®Google Scholar
• Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet363(9426), 2073–2075 (2004).
   PubMed Web of Science ®Google Scholar
• Kitchener S, Nissen M, Nasveld P et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine24(9), 1238–1241 (2006).
   PubMed Web of Science ®Google Scholar
• Halstead SV, Gubler D. Dengue vaccines. In: Vaccines. Plotkin S, Orenstein W, Offit P (Eds). Elsevier, Oxford, UK 1155–1161 (2008).
   Google Scholar
• Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr. Infect. Dis. J.23(2), 99–109 (2004).
   PubMed Web of Science ®Google Scholar
• Chanthavanich P, Luxemburger C, Sirivichayakul C et al. Short report: immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am. J. Trop. Med. Hyg.75(1), 26–28 (2006).
   PubMed Web of Science ®Google Scholar
• Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine18(Suppl. 2), 44–47 (2000).
   PubMed Web of Science ®Google Scholar
• Kanesa-Thasan N, Sun W, Kim-Ahn G et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine19(23–24), 3179–3188 (2001).
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Weltzin R, Chambers TJ et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol.74(12), 5477–5485 (2000).
   PubMed Web of Science ®Google Scholar
• Chambers TJ, Jiang X, Droll DA, Liang Y, Wold WS, Nickells J. Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice. J. Gen. Virol.87(Pt 11), 3131–3140 (2006).
   PubMedGoogle Scholar
• Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine20(7–8), 1004–1018 (2002).
   PubMed Web of Science ®Google Scholar
• McGee CE, Lewis MG, Claire MS et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J. Infect. Dis.197(5), 693–697 (2008).
   PubMed Web of Science ®Google Scholar
• Deauvieau F, Sanchez V, Balas C et al. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1–4. Am. J. Trop. Med. Hyg.76(1), 144–154 (2007).
   PubMed Web of Science ®Google Scholar
• Monath TP, Myers GA, Beck RA et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals33(3), 131–144 (2005).
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Zhang Z, Myers G et al. A single amino acid substitution in the envelope protein of chimeric yellow fever–dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J. Virol.78(18), 9998–10008 (2004).
   PubMed Web of Science ®Google Scholar
• Khromava AY, Eidex RB, Weld LH et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine23(25), 3256–3263 (2005).
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax–DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin.2(2), 60–67 (2006).
   PubMed Web of Science ®Google Scholar
• Kinney RM, Butrapet S, Chang GJ et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology230(2), 300–308 (1997).
   PubMed Web of Science ®Google Scholar
• Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3´ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol.70(6), 3930–3937 (1996).
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3´ untranslated region is highly attenuated and immunogenic in monkeys. J. Virol.77(2), 1653–1657 (2003).
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS, McArthur J et al. rDEN4d30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis.191(5), 710–718 (2005).
   PubMed Web of Science ®Google Scholar
• Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol.19(1), 10–32 (2006).
   PubMed Web of Science ®Google Scholar
• Markoff L, Pang X, Houng HS et al. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J. Virol.76(7), 3318–3328 (2002).
   PubMed Web of Science ®Google Scholar
• Putnak R, Barvir DA, Burrous JM et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis.174(6), 1176–1184 (1996).
   PubMed Web of Science ®Google Scholar
• Hombach J. Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev. Panam. Salud. Publica.21(4), 254–260 (2007).
   PubMed Web of Science ®Google Scholar
• Putnak R, Fuller J, VanderZanden L, Innis BL, Vaughn DW. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am. J. Trop. Med. Hyg.68(4), 469–476 (2003).
   PubMed Web of Science ®Google Scholar
• Hatch S, Mathew A, Rothman A. Dengue vaccine: opportunities and challenges. IDrugs11(1), 42–45 (2008).
   PubMedGoogle Scholar
• Monath TP, Kanesa-Thasan N, Guirakhoo F et al. Recombination and flavivirus vaccines: a commentary. Vaccine23(23), 2956–2958 (2005).
   PubMed Web of Science ®Google Scholar
• Deen JL. Editorial: the challenge of dengue vaccine development and introduction. Trop. Med. Int. Health9(1), 1–3 (2004).
   PubMedGoogle Scholar
• McMahon AW, Eidex RB, Marfin AA et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine25(10), 1727–1734 (2007).
   PubMed Web of Science ®Google Scholar
• Monath TP, Cetron MS, McCarthy K et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum. Vaccin.1(5), 207–214 (2005).
   PubMed Web of Science ®Google Scholar
• Martin M, Tsai TF, Cropp B et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet358(9276), 98–104 (2001).
   PubMed Web of Science ®Google Scholar